Core Viewpoint - A class action securities lawsuit has been filed against Krispy Kreme, Inc. due to alleged securities fraud affecting investors between March 26, 2024, and May 7, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Krispy Kreme's management made overly positive statements while concealing negative facts about the demand for its products at McDonald's locations [2] - It is alleged that lower demand at McDonald's led to a decline in average weekly sales per store, and the partnership with McDonald's was not profitable, causing Krispy Kreme to pause expansion plans [2] - Krispy Kreme reported a net revenue decline of $404 million, or 10.4%, and a decrease in average sales per door per week due to changing customer mix [2] Group 2: Stock Price Impact - Following the release of disappointing fourth quarter 2024 results, Krispy Kreme's stock price fell from $9.13 per share on February 24, 2025, to $7.13 per share on February 25, 2025 [2] - On May 8, 2025, after announcing a first quarter 2025 net revenue of $375.2 million, a decline of 15.3% or $67.5 million, the stock price dropped from $4.33 per share on May 7, 2025, to $3.26 per share on May 8, 2025, representing a decline of about 25% in one day [2] Group 3: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until July 15, 2025, to request to be appointed as lead plaintiff in the lawsuit [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 4: Law Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - A class action securities lawsuit has been filed against DoubleVerify Holdings, Inc. alleging securities fraud that negatively impacted investors between November 10, 2023, and February 27, 2025 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that DoubleVerify's customers shifted ad spending from open exchanges to closed platforms, where the company's technological capabilities were limited [2]. - It is alleged that the monetization of DoubleVerify's Activation Services was constrained due to the high costs and time required for technology development for closed platforms [2]. - The complaint states that DoubleVerify's competitors were better positioned to integrate AI into their offerings, which hindered DoubleVerify's competitive edge and profitability [2]. - The company is accused of systematically overbilling customers for ad impressions served to declared bots from known data center server farms [2]. - The risk disclosures provided by DoubleVerify were claimed to be materially false and misleading, presenting adverse facts as mere possibilities [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until July 21, 2025, to request to be appointed as lead plaintiff in the lawsuit [3]. - Participation in the class action does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Caleres, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] - Caleres reported a first-quarter 2025 sales figure of $614.2 million, which is a 6.8% decline year-over-year, and the CFO acknowledged this was below expectations [3] - Following the disappointing financial results, Caleres's stock price dropped by $3.00 per share, or 18.32%, closing at $13.38 per share on May 29, 2025 [3] - The company has suspended its guidance for 2025 due to uncertainty in the business environment [3] Company Overview - Caleres, Inc. is a publicly traded company listed on the NYSE under the ticker symbol CAL [1] - The company is currently facing scrutiny from investors and legal investigations related to its business practices [1] Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Unicycive Therapeutics and its officers or directors following a significant stock price drop after the FDA issued a Complete Response Letter for its New Drug Application [1][3]. Group 1: Company Overview - Unicycive Therapeutics, Inc. is a company listed on NASDAQ under the ticker UNCY [1]. - The company recently faced regulatory challenges when the FDA issued a Complete Response Letter for its New Drug Application for OLC, intended to treat hyperphosphatemia in patients with chronic kidney disease on dialysis [3]. Group 2: Regulatory Issues - The FDA's Complete Response Letter was issued due to deficiencies found at a third-party manufacturing vendor associated with Unicycive's contract development and manufacturing organization [3]. - Following the announcement of the FDA's decision, Unicycive's stock price fell by $2.03 per share, representing a decline of 29.85%, closing at $4.77 per share on June 30, 2025 [3]. Group 3: Legal Actions - Pomerantz LLP is actively seeking claims from investors of Unicycive regarding potential securities fraud or other unlawful practices [1]. - Investors are encouraged to contact Pomerantz LLP for participation in the investigation [1].

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BellRing Brands, Inc. ("BellRing" or the "Company") (NYSE: BRBR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether BellRing and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. On this news, BellRing's stock price fell $14.88 per share, or 18.97%, t ...

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Altimmune and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On this news, A ...

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Tesla, Inc. ("Tesla" or the "Company") (NASDAQ: TSLA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. On news of the NHTSA investigation, Tesla's stock price fell sharply, damaging investors. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of c ...

NEW YORK, July 14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP (NYSE: XIFR).Shareholders who purchased shares of XIFR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/xplr-infrastructure-lp-f-k-a-nextera-energy-partn ...

Core Viewpoint - Jasper Therapeutics, Inc. is under investigation for potential securities fraud and unlawful business practices following a significant drop in stock price due to issues related to a drug product lot in a clinical study [1][2]. Group 1: Company Overview - Jasper Therapeutics, Inc. is publicly traded on NASDAQ under the ticker symbol JSPR [1]. - The company recently reported updated data from its BEACON Phase 1b/2a study of briquilimab, which is intended for adult participants with chronic spontaneous urticaria (CSU) [2]. Group 2: Recent Developments - On July 7, 2025, Jasper announced that results from certain dose cohorts of its clinical study were confounded by issues with a specific drug product lot, affecting 10 out of 13 patients in those cohorts [2]. - Following this announcement, Jasper's stock price plummeted by $3.73 per share, representing a 55.1% decrease, closing at $3.04 per share on the same day [2]. Group 3: Legal Context - Pomerantz LLP is investigating claims on behalf of Jasper investors, focusing on potential securities fraud and misconduct by the company and its officers or directors [1]. - The Pomerantz Firm has a long history in corporate and securities class litigation, having recovered significant damages for victims of securities fraud [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices by Brown-Forman Corporation and its officers or directors, following disappointing financial results that led to a significant drop in stock price [1][2]. Financial Performance - Brown-Forman reported a 7.3% year-over-year decline in sales for fiscal year 2025, with earnings per share of $0.31, which fell short of consensus estimates [2]. - The company acknowledged that its results did not meet long-term growth aspirations and indicated expectations of continued headwinds for fiscal 2026 [2]. Legal Investigation - Pomerantz LLP, a prominent firm in corporate and securities class litigation, is leading the investigation on behalf of investors who may have been affected by Brown-Forman's alleged misconduct [1][3].